DNM0904

DNM0904 is a preclinical **small-molecule antibiotic** being developed by DeNovaMed for systemic treatment of difficult bacterial infections. It is described as targeting **ACP synthase**, a bacterial enzyme involved in lipid metabolism that is not targeted by current antibiotics. DeNovaMed reports activity against **Gram-positive systemic infections**, including MRSA and multidrug-resistant strains, and notes **synergy with colistin** against multidrug-resistant **Gram-negative pathogens** including *Escherichia coli*, *Klebsiella pneumoniae*, and *Acinetobacter baumannii*, with reported activity against **colistin-resistant strains**. The company pipeline also lists development interest in **leprosy** and **anthrax**.